A study designed to test cell migration should not be used as primary evidence for proliferation unless proliferation-specific measurements are included
In leptin-deficient ob/ob mice, sitagliptin at 50 mg/kg daily for 4 weeks ameliorated weight gain, metabolic disorders, and steatosis in the liver as well as insulin sensitivity
Alternative GLP-1 receptor agonists If semaglutide causes significant side effects or concerns about b12 status arise, other GLP-1 medications offer alternatives
These landmark studies established that GLP-1 medications deliver clinically significant results in non-diabetic populations, leading to FDA recognition of semaglutide and tirzepatide as weight loss agents independent of diabetes status
"The growth hormone/IGF-1 axis is an attractive target for preserving muscle mass in cirrhosis, but the liver's dual role as both a GH effector organ and a metabolic clearance site means that any GH-axis intervention must account for the degree of hepatocellular dysfunction," according to the Endocrine Society's position statement on GH in chronic illness (Endocrine Society Clinical Practice Guideline, 2011)